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Abstract: Glutamine Synthetase 1 (GS1) is a key enzyme that catalyzes the ATP-dependent synthesis
of l-glutamine from l-glutamate and is also member of the Glutamate Glutamine Cycle, a complex
physiological process between glia and neurons that controls glutamate homeostasis and is often
found compromised in neurodegenerative diseases including Huntington’s disease (HD). Here we
report that the expression of GS1 in neurons ameliorates the motility defects induced by the expression
of the mutant Htt, using a Drosophila model for HD. This phenotype is associated with the ability
of GS1 to favor the autophagy that we associate with the presence of reduced Htt toxic protein
aggregates in neurons expressing mutant Htt. Expression of GS1 prevents the TOR activation and
phosphorylation of S6K, a mechanism that we associate with the reduced levels of essential amino
acids, particularly of arginine and asparagine important for TOR activation. This study reveals a
novel function for GS1 to ameliorate neuronal survival by changing amino acids’ levels that induce a
“starvation-like” condition responsible to induce autophagy. The identification of novel targets that
inhibit TOR in neurons is of particular interest for the beneficial role that autophagy has in preserving
physiological neuronal health and in the mechanisms that eliminate the formation of toxic aggregates
in proteinopathies.
Keywords: Huntington’s disease; glutamine synthetase 1; autophagy; TOR signaling; protein
aggregates; Drosophila model for neuronal degeneration
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1. Introduction
Huntington’s disease (HD) is an inherited neurodegenerative disease with a middle age clinical
onset that highly depends upon the length of the CAG repeated sequence (>35) present in the first exon
of the huntingtin gene (OMIM 143100) [1]. Mutations in the gene that expands this sequence result in a
protein with a long poly-Q trait that forms toxic mHTT protein aggregates which are considered as
one of the major cause for the progressive degeneration of neurons, particularly of the striatum and
cortex, resulting in cognitive decline and motor defects [2–4]. Drugs as antisense oligonucleotides [5]
have been recently developed to slow down the disease progression, and attention is dedicated to
those that ameliorate neuronal survival by increasing autophagy to limit the formation of mHTT
aggregates [6–10].
Neuronal health depends also upon maintaining glutamate at physiological levels; a process that
is controlled by a sequence of biochemical reactions, called the Glutamate–Glutamine Cycle (GGC),
occurring between glia and neurons that often are found altered in neuronal pathology [11]. Key
components of the GGC are the enzymes Glutamine Synthetase-1 (GS1) that uses ammonia to convert
glutamate into glutamine with the hydrolysis of ATP, Glutamate dehydrogenase (GDH), that coverts
glutamate into alfa-keto glutarate (aKG), and Glutaminase (GLS) that in neurons produces glutamate
from glutamine [12]. Since the activity of GS1 was found reduced in neuronal diseases [13] and in the
postmortem brains of patients with HD [14–16], we decided to investigate the contribution of GS1 to
HD, using a well-established Drosophila model for HD that expresses the exon1 of the human HTT
gene with 93 CAG repeats, (hereon referred to as Htt-Q93). This model recapitulates the cellular and
molecular events described in HD, including the loss of neurons and impaired animal motility [17].
Gs1 is a conserved enzyme, from bacteria to vertebrates, and in Drosophila there are two distinct
genes, Gs-1 and Gs-2, encoding for glutamine synthetases, both highly homologous to the human gene
GLUL (60.5%) [18]. Here we show that the expression in neurons of GS1 together with Htt-Q93
significantly improves animal motility and rescues neuronal loss. At the cellular level, we found that
GS1 increases the level of autophagy, and significantly reduces the size of Htt-Q93 protein aggregates.
Autophagy is induced when amino acid levels are low, and in neurons it plays an important role
for the survival and homeostasis of these post-mitotic cells, while its activation is counteracted by
TOR signaling and nutrients [19]. Activation of TOR by amino acids induces the assembling of the
RagA/B-C/D GTPases complex that, together with the GTPase Rheb, activates the TORC1 complex at
the lysosomal membrane [20,21] to phosphorylate S6K and 4EBP target proteins [22]. Interestingly,
we found that the expression of GS1 in neurons was able to reduce TOR signaling, measured by the
reduced level of S6K phosphorylation, a mechanism that was present also when GS1 was co-expressed
with Htt-Q93. Analysis of the amino acid levels in the heads of animals expressing GS1 in neurons
reveals a significant decrease of essential amino acids, including proline and arginine, known to be
necessary in the mechanism of TOR activation. Finally, we show that GS1 protein levels are reduced in
human fibroblasts from HD patients, and these cells have impairment in the autophagy flux, suggesting
that the role of GS1 in the control autophagy may be conserved also in human cells.
In summary, our data propose a novel function for GS1 in neurons that links its activity to
mechanisms that activates autophagy and the reduction of Htt-Q93 toxic aggregates. Understanding
how GS1 controls amino acids signaling in neurons is the initial step to comprehend a novel function
for this enzyme, member of the GGC, in the control of autophagy and neuronal survival. Ultimately,
this would be relevant not only for the control of pathological diseases such as HD, but also in the
mechanisms that regulate physiological neuronal health and aging.
2. Materials and Methods
2.1. Fly Husbandry and Lines
Animals were raised at low density, at 25 ◦C, on a standard food medium containing 9 g/L agar
(ZN5 B and V, Gatattico (Re), Italy), 75 g/L corn flour, 60 g/L white sugar, 30 g/L brewers’ yeast (Fisher
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Scientific Italia, Rodano (Mi), Italy), 50 g/L fresh yeast and 50 mL/L molasses (Biosigma, Cona (Ve),
Italy), along with nipagin and propionic acid (Fisher, Rodano (Mi), Italy). The following fly lines were
obtained from the Bloomington Drosophila Stock Center: UAS-Htt-16Q (B33810), EP-GS1(G33347) an
enhancer-promoter (EP)-line with an insertion of the P-element, carrying a UAS enhancer sequence and
a basal promoter, in the GS1 locus allowing the expression of GS1 by Gal4 (B27940), UAS-GS1-RNAi
(B40836), UAS-mCherry-Atg8a (B37750), elavc155-Gal4 on the X ch. (B458) and GMR-Gal4 (B9146).
Fly lines bearing the UAS-Htt-Q93 was a gift of from L. Marsh (University of California, Irvine),
UAS-GFP-LAMP1 and UAS-Atg1-RNAi where a gift from F. Parisi (Beatson Institute for Cancer Research,
Glasgow, UK), UAS-Atg5-RNAi was a gift from T. Neufeld (University of Minnesota). EP-FOXO [23]
was a gift from Hugo Stocker (ETH-Zurich).
2.2. Survival at Eclosure Analysis
The number of animals and their timing of eclosion from every cross with the elavc155-Gal4 driver
were quantified, and the percentage of animals eclosed was calculated for each of the genotypes of
interest with respect to the expected number of animals that did eclose.
2.3. Motility Assays
Ten larvae (3rd instar) were collected, washed with phosphate-buffered saline (PBS) and then
transferred to a 14 cm Petri dish containing 1% agarose in PBS, where a visible grid was drawn to
portray the arena (Supplementary Figure S4). The number of lines crossed by one larva in 1 min at
room temperature was counted. Statistical analysis was performed with the Student’s t-test; values
for each genotype are represented as mean ± standard deviation (SD). Experiments were repeated
at least three times. For motility assays with adult animals, 10–15 females were collected at 1 day
after eclosion (DAE), transferred in a plastic vial, and their ability to climb up the empty vial after a
knock-down to the bottom was analyzed, using the protocol previously described in Zhang et al., [24].
The number of flies that were able to climb half of the tube in 15 s was counted. Values were expressed
as the percentage of success with respect to the total number of flies in the vial. For each genotype the
test was repeated 30 times for each time point. After the test, adults were transferred in vials with
food, and these vials were changed every two days. Data are represented as a curve of progressive
motility impairment. The statistical analysis of variance (one-way analysis of variance (ANOVA) was
performed using PRISM 7 GraphPad Software (San Diego, CA, USA). Every experiment was repeated
at least six times. The experiments were performed only using females, as in males the expression of
Htt-Q93 resulted in a low survival rate, and elav/Y; Htt-Q93/+ males showed 50% reduction of their
climbing activity at 2–3 DAE, and that were not further used (Supplementary Figure S6). The stronger
effect of Htt-Q93 in males is probably due to the dosage compensation that affects genes expressed on
the X chromosome where the transgene elav-Gal4 is inserted [25].
2.4. Quantification of Fluorescence (GFP) on the Adult Compound Eye
Photographs of adult eyes expressing the indicated UAS-transgenes in the retina, and co-expressing
UAS-GFP using the GMR-Gal4 promoter, were taken at 8 days after eclosion using a Leica
stereomicroscope MZ10F with a fluorescent source and a camera, and by employing 5×magnification.
The intensity of fluorescence in each image was quantified as the integrated density from an area
containing 20 ommatidia using Adobe Photoshop-CS4, and expressed as a GFP intensity/area. At least
10 eyes (one for each animal) were used for each genotype, and these experiments were repeated twice.
2.5. Western Blot
Proteins were extracted from ten larval brains or from ten adult heads, collected in lysis buffer
(50 mM Hepes/NaOH pH 7.4, 250 mM NaCl, 1 mM ethylenediaminetetraacetic acid (EDTA), 1.5%
Triton X-100 containing a cocktail of phosphatases inhibitors (PhosSTOP #04906837001, Merck Life
Science, Darmstadt, Germany) and proteases inhibitors (Roche, cOmplete #04693132001, Merck Life
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Science, Darmstadt, Germany). For the detection of the huntingtin protein, lysates were extracted
using 2% sodium dodecyl sulfate (SDS) lysis buffer (50 mM Hepes/NaOH pH 7.4, 250 mM NaCl, 1 mM
EDTA, 2% SDS containing phosphatases and proteases inhibitors). Samples were sonicated three times
for 10 s using a Branson Ultrasonic Sonifier 250 (Branson, Darbury, CA, USA) equipped with a microtip
set at 25% power. Tissue and cell debris were removed by centrifugation at 10,000× g for 30 min at 4 ◦C.
Proteins in the crude extract were quantified by a bicinchoninic acid (BCA) Protein assay Reagent Kit
(Pierce), following the manufacturer’s instructions with bovine serum albumin as the standard protein.
For SDS-PAGE, samples were incubated for 8 min at 100 ◦C in standard reducing loading buffer; 40 µg
of total protein were run on a SDS-polyacrylamide gel and transferred onto nitrocellulose membranes
(GE-Healthcare, Fisher Scientific Italia) After blocking in 5% (w/v) non-fat milk in tris-buffered saline
(TBS)-0.05% Tween (TBS-T), membranes were incubated overnight with primary antibodies against:
hHTT (1:500, ab109115), GABARAB (1:500, ab109364) that cross-reacts with Drosophila Atg8a [26,27],
GS1 (1:800, ab64613) from Abcam, Cambridge, UK; Elav (1:100, #9F8A9), Synapsin (1:100, #8C3),
Actin5c (1:200, #JL20) from Developmental Studies Hybridoma Bank (DSHB), University of Iowa, IA,
USA. SQSTM1/p62 (1:500, #5114), Drosophila p70-S6K (1:500, #9209), ATG1 (1:500, #8054) from Cell
Signaling, Euroclone (Mi) Italy; Tubulin (1:500, MAB3408) from Chemicon, DBA Italia, Segrate (Mi),
Italy; and ATG5 (1:500, OSA00026W) from Thermo Fisher Monza, Monza, Italy.
2.6. Filter Trap Assay
Ten larval brains or ten adult heads for each genotype were homogenized in lysis buffer (50 mM
Tris- HCl pH 6.8, 2% SDS plus proteases and phosphatases inhibitors). Fifty micrograms of protein
extracts were loaded on a dot–blot device and filtered through a cellulose acetate membrane (0.22 µm
pore size), previously washed in 1% (w/v) SDS solution in PBS. After filtration, membranes were
washed three times in TBS-T, saturated in 5% non-fat milk and processed for immunodetection with
anti-Htt antibodies from Abcam, as described above.
2.7. Patient-Derived Cell Lines
Fibroblasts from patient and controls were derived from skin biopsies and grown in the Dulbecco’s
modified Eagle’s medium (DMEM)-high glucose or galactose media, as described previously in Wong
et al., [28]. Each individual providing a biological sample signed a written, informed consent approved
by the Institutional Review Board of the Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan,
Italy, in agreement with the Declaration of Helsinki.
2.8. MS/HPLC for Glutamate and Glutamine Quantification and Analysis of Amino Acids
Ten heads from animals at eight DAE were resuspended in 100 µL of Hepes/NaOH with proteases
and phosphatases inhibitors, samples were disrupted using a mechanical tip following two rounds of
sonication of 10 s each. After centrifugation at 13,000 rpm for 30 min at 4 ◦C, 20 µL of each sample were
set aside for Bradford analysis, while supernatants were diluted in buffer containing DL-Lysine D4 and
DL-Ornitine D6 as internal standards (Eurisotop, Cambridge Isotopes Labs, Inc., Cambridge, UK) and
2/3 v/v of methanol, to precipitate the proteins. After centrifugation, amino acid analysis was performed
on a Perkin Elmer Series 200 HPLC equipped with a 4 µm, 2.0× 75 mm Synergi Polar-RP (Phenomenex,
Bologna, Italy) column, and coupled with triple quadrupole API2000 tandem mass spectrometer and
AB SCIEX analyst software (version 1.4) for data acquisition analysis (AB SCIEX, Framingham, MA,
USA). Analysis of free amino acids was performed by Innovhub, Stazioni Sperimentali per Industria,
Milan (Italy) with the following protocol: 30 heads of each genotype were resuspended in 300 µL of
HPLC-grade H2O, samples were disrupted using a mechanical tip following two rounds of sonication
of 10 s each.
20 µL were set aside for Bradford analysis, while 75 µL of a 6% solution of sulfosalicylic acid
were added to the final concentration of 1.5%. Samples were centrifuged for 20 min at 13,000
rpm, and supernatants were used for the analysis. The protocol applied (UNI 22615:1992) uses
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ionic exchange chromatography where the amino acids are separated by chromatography using an
automatic Lithium High Performance Physiological Column with the instrument Biochrom 30+ from
Biochrom. The separation is based on using Lithium Citrated buffer solutions employing a five steps
pH separation from pH 2.80 up to pH 3.55. Amino acids were visualized on TLC using ninidrin and
detected at 440 and 570 nm.
2.9. Quantitative Real Time PCR
Total RNA was isolated using the RNeasy Mini Kit (Qiagen Italia, Milano, Italy) according
to the manufacturer’s instructions. Extracted RNAs were quantified using an ultraviolet (UV)
spectrophotometer, and RNA integrity was confirmed with ethidium bromide staining. The purified
RNA (1 mg) was used as the template for cDNA using SuperScript II (Invitrogen, San Diego, CA, USA,
Thermo Fisher, Waltham, MA, USA). The SYBR Green PCR Kit (Qiagen) was used, and products were
quantified utilizing the BIO-RAD system. The quantitative reverse transcription polymerase chain
reaction (qRT-PCR) sample values were normalized for the expression of actin-5C mRNA. The relative
level for each gene was calculated using the 2-DDCt method [29] and reported as arbitrary units. Three
separate samples were used in triplicate. Primers sequences are reported in Parisi et al., [30].
2.10. Quantification of GS1 Activity
Drosophila larvae or heads that had been flash frozen in liquid nitrogen were resuspended in
200 µL 50 mM Hepes/NaOH buffer, pH 7.4 and 0.5% protease inhibitors cocktail (Roche, cOmplete
#04693132001 Merck, Milano, Italy). They were homogenized with a Branson 250 sonifier equipped
with a microtip (25% power, 20% duty cycle) by applying four series of 10 sonication pulses and
controlling the temperature by immersion in an ice bath. The homogenate was centrifuged in a
microfuge at 13,000 rpm for 30 min at 4 ◦C and passed through an Ultrafree-MC (Millipore UFC306V,
Merck, Milano, Italy) filter device by centrifuging at 11,000 rpm for 15 min at 4 ◦C. The filtrate was used
for protein and activity assays. Protein concentration was determined with the Bradford method and
bovine serum albumin as the reference protein. Glutamine Synthetase (GS) activity was assayed by
quantifying the amount of γ-glutamylhydroxyamate (GGHA) produced as described in Vorhaben et al.,
Caizzi et al., and De Pinto et al., [31–33]. In preliminary experiments a range of GGHA concentrations
(0.07–0.15 mM) was used to determine the sensitivity and linear range of the assay. Briefly, a known
amount of crude extract (0.1–0.5 mg in up to 120 µL) was incubated for 1 h at 37 ◦C in 50 mM Tris/HCl
buffer, pH 7.5, hydroxylamine (40 mM final concentration), MgCl2 (40 mM) L-glutamate (20 mM) and
ATP (5 mM) in a final volume of 600 µL. The reaction was blocked by adding 200 µL of FeCl3 solution
(3.3% FeCl3, 8% trichloroacetic acid (TCA), 0.67 M HCl) and centrifuged at top speed for 10 min. The
amount of GGHA produced was calculated from the absorbance value at 500 nm and 600 nm with the
HP 8453 diode array spectrophotometer using the reported extinction coefficients of 1.004 mM−1cm−1
and 0.471 mM−1 cm−1 for the crude extracts derived from larvae and heads, respectively; by monitoring
the entire spectrum of the final solution, we ensured that no artifacts arose from turbidity, precipitation
or the presence of pigments, especially with Drosophila heads. For each assay a blank devoid of L-Glu
and ATP was set up, and the measured absorbance was subtracted to that of the corresponding sample
prior to the calculation of the activity value. The extracts were selected in order to ensure that the
GGHA concentration increase was linear with respect to the incubation time. l-Methionine sulfoxide
(MSO) was added to reaction mixtures at a final concentration of 1 mM (from 10 mM stock solution
in 50 mM Hepes/NaOH buffer, pH 7.4) to test its effect on GS1 activity. Activity was expressed as
milliunits/mg protein, where 1 unit of GS activity is the amount of GS that converts 1 µmol l-Glu into
product per minute.
GS activity detected in wild-type larvae was taken as 100% activity to normalize the values
obtained with different larvae batches and in comparison with the values measured with transfected
larvae. For each sample, replicates differed by less than 15%. GS1-specific activity in the heads of adult
Cells 2020, 9, 196 6 of 23
females was analyzed in the presence of the specific GS1-inhibitor methionine sulfoximine (MSO), as
shown in Supplementary Figure S7.
2.11. Immunofluorescences and Quantification of the Size of Htt-Q93 Aggregates
Brains from third instar larvae were dissected and fixed for 30 min in 4% paraformaldehyde (PFA)
on ice. After tissues permeabilization with 0.5% Triton X-100, samples were washed in PBS-0.1% Tween20
(PBST) and blocked in 3% BSA (in PBST) for 30 min on ice. Samples were incubated with anti-Htt
antibody in 3% BSA overnight at 4 ◦C. After three washes of 10 min each in PBST, the samples were
incubated with mouse or rabbit secondary antibodies Alexa 555 (Invitrogen) 1:400 in 3% BSA for 2 h and
at room temperature (RT) on the shaker. After extensive washing with PBST, brains were mounted on
slides in 20 mL of Mowiol. Nuclei were stained with Hoechst 33258 added at the final concentration
of 1µg/mL. The quantification of the mHtt aggregates visualized by fluorescence upon staining with
anti-human Htt antibodies and secondary anti-rabbit Alexa 555, was performed on z-stacks acquired
under a confocal microscope, by keeping the acquisition parameters constant. The intensity of the red
aggregates was quantified from the confocal stacks using ImageJ 1.50i software (Wayne Rasband NIH,
Bethesda, MA, USA) inside a square of fixed size (300 × 300 pixels), which was moved in four different
regions in the specific area of the brain (calyx, VNC or IL). The aggregates were quantified by measuring
the intensity of the fluorescent signal in these different regions (integrated density-IntDen tool on ImageJ).
The integrated density of the fluorescence acquired was considered directly proportional to the aggregate
number. Statistics was applied using as a threshold the IntDen in the control animals.
2.12. Statistical Analysis
Student t-test analysis and analysis of the variance calculated using One-way ANOVA with Tukey
multi-comparisons test (the whole ANOVA analysis is reported in the Supplementary Excel 1) were
calculated using GraphPad-PRISM 7. p values are indicated with asterisks * p < 0.05, ** p < 0.01,
*** p < 0.001, **** p < 0.0001, respectively.
2.13. Autophagy Analysis
elav-Gal4; UAS-GFP; UAS-mCherry-Atg8a females were crossed with males carrying the appropriate
UAS-transgenes. Third instar larvae (72–80 h after hatching) were collected and washed, and then their
brains were dissected in phosphate-buffered saline (PBS) buffer. Brains were fixed for 30 min in 4%
paraformaldehyde (PFA) on ice. Nuclei were stained with Hoechst 33258, samples mounted in Mowiol
and images acquired using a confocal microscope (SM5 LEICA Leserteknik GmbH, Wetzlar, Germany)
using ImageJ 1.50i software or AdobePhotoshop-CS4. The quantification of autophagic puncta stained by
mCherry-Atg8a and representing the autophagosomes, was performed on z-stacks acquired under a
+confocal microscope, by keeping the acquisition parameters constant. The intensity of the autophagic
puncta was quantified with the software ImageJ inside a square of fixed size (300 × 300 pixels), which
was moved in four different regions in the specific area of the brain (calyx, VNC or retina). Autophagy
was quantified by measuring the intensity of the fluorescent signal in these different regions (integrated
density-IntDen tool on ImageJ) using four out of five brains for each genotype of interest. Statistics
was applied using as a threshold the IntDen in the control animals
3. Results
3.1. GS1 Rescues Neuronal Death Induced by Expression of Htt-Q93 in the Retina
In post mortem brains from HD patients, the expression of the enzyme glutamine synthetase
(GS1) was found reduced. In order to evaluate the potential role of GS1 in HD we expressed the
Drosophila, homolog of the human GLUL gene (Supplementary Figure S1), in neurons of the retina
using a well-established model for HD. These animals expressed exon1-of the human huntingtin gene
containing 93 repetitions of the CAG sequence, herein called Htt-Q93 and were shown to recapitulate
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phenotypes of the disease including neuronal loss and motility defects [34,35]. As shown in Figure 1,
ubiquitous expression of Drosophila GS1, using the EP-GS1-G3347 line, hereon called UAS-GS1, resulted
in a twofold increase in Gs1-mRNA (Figure 1A) and in a 50 KDa protein recognized by anti-human GS1
antibodies (Figure 1B). Analysis of GS1 enzymatic activity showed a significant increase compared to
that in control w1118 animals (Figure 1C), suggesting that the EP-GS1-G3347 line is expressing an active
Drosophila GS1 enzyme.
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Figure 1. Expression of GS1 in the retina rescues neuronal death induced by Htt-Q93. (A) Quantitative
reverse transcription polyme se chai reaction (qRT-PCR) analysis of GS1 mRNA expression in larvae
from control w1118 of animals expressing the EP-GS1G4337 (GS1) line using the actin-Gal4 driver. The
relative level of GS1-mRNA is reported as arbitrary units compared to actin5C used as a control. At least
three separate experiments were performed in duplicate. (B) Western blot from larvae extracts showing
the relative amount of GS1 protein from w1118 (CTL) animals or expressing GS1. Tubulin was used as
the loading control. (C) GS1 enzymatic activity in extracts from whole larvae used in (A,B). *** p < 0.001,
**** p < 0.0001 in panels (A,C) were calculated from Student’s t-test from at least three independent
experiments.(D–G)) Photographs of Drosophila-compound eyes (lateral view) from females at 20 days
after eclosion (DAE) expressing the indicated UAS-transgenes using the GMR-Gal4 driver. (H–K)
Representative photographs of the retina from animals of the indicated genotype. (L) Fluorescent
image of a fly head expressing UAS-GFP under the GMR-Gal4 promoter (sagittal view), bar 100 µm.
(M) Quantification of GFP from photographs of adult eyes at 20 DAE of the indicated genotypes. The
asterisks represent the p-values from One-way analysis of variance (ANOVA) with Tukey multiple
comparison * p < 0.05 and **** p < 0.0001, and the error bars indicate the standard deviations.
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When UAS-GS1 was co-expressed with UAS-Htt-Q93 in the retina using the GMR-Gal4 promoter,
we observed a complete rescue of the reduced pigmentation visible in the ommatidia of Htt-Q93 animals
(compare Figure 1E with Figure 1F). On the contrary, reducing GS1 expression together with Htt-Q93
exacerbated these defects, and animals showed a premature loss of pigment cells and eye morphology
defects, in that at 8 days after eclosion, it was similar to that of animals expressing UAS-Htt-Q93 at
20 days (Supplementary Figure S2). An ultramicroscopic analysis showed that expression of GS1
ameliorated also the alteration of the cornea morphology induced by Htt-Q93 expression and visualized
by the presence of large vacuoles indicating cell loss (Figure 1I,J). Morphological analysis of the retina
from UAS-GS1 and control UAS-Htt-Q16 animals revealed no defects (Figure 1H,K, respectively).
Neuronal death can be indirectly analyzed by measuring the decrease over time of the fluorescence
emitted by the Green Fluorescent Protein (GFP) when co-expressed with Htt-Q93 [35] (Figure 1L).
These experiments showed that co-expression of GS1 completely rescued the reduction in GFP induced
by Htt-Q93 (Figure 1M, ANOVA p < 0.0001), while we did not observe any significant difference in the
quantification of GFP in the ommatidia of control GMR-Q16 or GMR-GS1 animals. A representative
image for each genotype is shown in Supplementary Figure S3.
3.2. GS1 Expression in Neurons Improves Locomotion Defects of Htt-Q93 Animals
We next extended our analysis to all neurons using the elavc155-Gal4 pan-neuronal promoter (hereon
referred as elav-Gal4) [34]. Western blot analysis on extracts from larval brains from elav-Htt-Q16 and
elav-Htt-Q93 animals showed the presence of a 35 KDa and 55 KDa proteins, respectively, recognized
by anti-human HTT antibodies. In addition, a high-molecular-weight protein-complex > 250 KDa
(HMW-mHtt) was visibly entrapped in the stacking gel, where extracts from elav-Htt-Q93 animals were
loaded, and almost no reduction in the HMW-mHtt was detected when Htt-Q93 was co-expressed
with GS1 (Figure 2A), suggesting that GS1 was only partially able to reduce the high molecular weight
form of HMW-mHtt aggregates at this stage of expression.
Since one characteristic of HD is the progressive impairment of movement [34], we investigated
whether expression of UAS-GS1 could rescue the motility defects in third instar larvae expressing
UAS-Htt-Q93 in neurons by performing motility assays. These experiments showed that the expression
of GS1 was able to fully rescue these defects that in elav-Htt-Q93 larvae are already visible at 48–72 h
after egg laying (AEL) (Figure 2B, ANOVA p < 0.0001 and Supplementary Figure S4 and Supplementary
Video S1 and S2). In addition, UAS-GS1 also rescued the developmental lethality visible in elav-Htt-Q93
animals (Figure 2C, ANOVA p < 0.05). No defects in morphology or motility were observed in larvae
expressing UAS-GS1 or UAS-Htt-Q16.
Western blot analysis on proteins extracted from the heads of adult females showed a pattern of
expression for Htt-Q16 and Htt-Q93 that was similar to that found in the larval brains (Figure 2D).
In addition, GS1 protein was expressed with a similar amount in the lysates from animals expressing
UAS-Htt-Q93 together with UAS-GS1 or UAS-GS1 alone (Figure 1E). Analysis of the relative GS1
enzymatic activity showed a similar increased in extracts from animal expressing UAS-GS1 alone and
those expressing UAS-GS1 together with UAS-Htt-Q93 indicating that GS1 was expressed with a similar
activity in both genotypes (Figure 2F, ANOVA p < 0.05). Finally, we analyzed the climbing activity
on adult females (Supplementary Figure S4 and Supplementary Video S3). This data showed that
elav/+; Htt-Q93 animals presented a 50% reduction in their motility at 8 days after eclosion (Figure 2G,L,
ANOVA p < 0.0001), that was extended up to 14 days by expression of GS1 (Figure 2G, ANOVA
p < 0.05); a similar effect for GS1 was observed in the rescue of animal survival (Figure 2H, ANOVA
p < 0.05 and panel L). Flies expressing GS1 alone or Htt-Q16 did not show any visible alterations in
their motility or viability.
We then analyzed indirectly, the ability of GS1 to rescue neuronal death by quantifying in western
blot the expression of the neural proteins Elav and Synapsin (Figure 2I) in the adult heads. This data
showed that, co-expression of GS1 rescued the reduced level of Elav (69%) and of Synapsin (38%)
proteins detected in Htt-Q93 corroborating its function on neuronal survival.
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Figure 2. Expression of GS1 in neurons rescues motility defects and neuronal death induced by Htt-Q93.
(A) Western blot showi g the relative amounts of the protein huntingtin i lysates from 20 third instar
larval brains expressing the indicated transgen s using the pan-neuronal driver elav-Gal4. Tubulin
was used as the loading co trol. The band of about 30 KD in lane 1 represents the Htt-Q16 prot in,
while the band at 55 KDa, in lanes 2 and 3, represents the Htt-Q93 protein. The high molecular weight
proteins recognized by the anti-hHTT antibody also present in lanes 2 and 3 represent the mutant Htt
high form that jammed in the stacking gel (indicated by a black line on the side). The 150 KDa band
present in all the lanes is aspecific, since it is recognize by the mHtt antibody also in lane 4 where Htt is
not expressed. A similar description is applied to the Western in Figure 2D. (B) Quantification of the
motility in third instar larvae of the indicated genotype, where the data are expressed as the distance
traveled in one minute measured in mm, and 10 larvae from each genotype were used the experiment
was repeated three times (see Supplementary Figure S4C–E, movies S1 and S2). (C) Eclosion timing
of adult females of the relative genotypes. (D,E) Western blots showing the respective amounts of
huntingtin and GS1 proteins in lysates from 15 heads for each genotype, of females at 8 days after
eclosion (DAE), wherein actin and tubulin were used as a loading control, respectively. In 2E is visible
a band of about 30–40 KDa only when the UAS-GS1 transgene is expressed (lane 3 and 4). The band at
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the higher molecular weight of about 55 KDa is either the endogenous Drosophila GS1 that is recognized
by the anti-human GS1 antibody, or an aspecific band, since it is present in all the lanes also where GS1
is not overexpressed. (F) GS1 enzymatic activity (mUnits/mg of total proteins) in lysates from heads of
females at 8 DAE, data show the significant increase of GS1 activity (brown) in these animals compared
to that in the heads of un-transfected control Q16 animals (black bar), and from Htt-Q93 (red) or Htt-Q93
co-expressing GS1 (purple). The * = p < 0.05 values in (F) were calculated from Student’s t-test from
at least three independent experiments, and error bars indicate the standard deviations. (G) Motility
assay on adult females, where data are expressed as % of success to the motility in control animals. (H)
Analysis of adult lethality is expressed as the % of survival of females relative to control. The ability
of GS1 to ameliorate the motility of Htt-Q93 was confirmed using three independent Htt-Q93, GS1
recombinant lines (Supplementary Figure S8). (I) Western blot showing the amounts of endogenous
neuronal specific proteins elav and synapsin in lysates extracted from fifteen heads of the indicated
genotype, actin and tubulin were used as control, and the % of reduction of the relative protein is
calculated compared to that in control animals where is considered equal to 1. (L) Table reporting
ANOVA for the data in panels G and H. The **** p < 0.0001 and * p < 0.05 values in panels (B,C,F) were
calculated using one-way ANOVA with Tukey multiple comparison from at least three independent
experiments, and error bars indicate the standard deviations.
3.3. Expression of GS1 Reduces Htt-Q93 Protein Aggregates in Neurons
Mutant huntingtin protein forms toxic intracellular aggregates that largely contribute to neuronal
death. Using the elav-Gal4 promoter, that is transcriptionally active in neurons and in the gigantic
cells of the salivary glands, we expressed UAS-Htt-Q93 together with membrane UAS-GFP and
used an anti-human Htt antibody to detect the presence of Htt-Q93 protein aggregates (mHtt) by
immunofluorescence (Figure 3A–D,F,G).
At 72 h of development, mHtt-aggregates were clearly visible in the cytoplasm and in the nuclei
of the cells of the salivary gland (SG) (Figure 3A) and in the cells of the calyx of Htt-Q93 animals
(Figure 3B), but absent in cells of the calyx from Htt-Q16 larvae (Figure 3C). The ability of GS1 to
modify the formation of Htt Q93 aggregates was analyzed by quantifying mHTT immunofluorescence
in neurons from the Intra-Lobe (IL), and from the Ventral Nerve Cord (VNC) (Figure 3F). This analysis
was performed using the signal for the integrated density of the fluorescence acquired from z-stacks
using a defined threshold that considers the number and size of the aggregates. This analysis showed
that co-expression of GS1 with Htt-Q93 significantly reduced the number of mHtt aggregates, in
neurons from the IL (Figure 3G,H, t-student, p < 0.01) and from the VNC (Figure 3I, t-student, p < 0.01).
To support these results we performed a filter-trap assay, a technique that is used to trap large protein
aggregates on a cellulose acetate membrane where they can be visualized by immunoblot. These
experiments showed that the co-expression of GS1 reduced the amount of large Htt-Q93 aggregates
trapped on the membrane, while no Htt-Q93 aggregates were detected in extracts from the brains of
animals expressing UAS-Htt-Q16 or UAS-GS1 alone (Figure 3J). Similar experiments were performed
in adult animals using extracts from females’ heads at 10 DAE. These experiments indicate that GS1
significantly reduces the presence of Htt-Q93 aggregates (Figure 3M, integrated analysis in analysis 3J,
t-student, p < 0.001), suggesting that its ability to control the formation of the toxic Htt-Q93 aggregates
is conserved though development.
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Figure 3. Expression of GS1 in neurons reduces the presence of Htt-Q93 aggregates. (A) Confocal
microscopy images of cells from the salivary gland (SG), where the elav-Gal4 insertion is also
transcriptionally active, showing the presence of Htt-Q93 protein aggregates (red), that are visible
in the cytoplasm and in the nuclei of cells expressing UAS-Htt-Q93 and UAS-GFP, immunostained
with anti-hHtt antibodies. Nuclei are stained with 4′,6-diamidino-2-phenylindole (DAPI); bar 30 µm.
(B) Htt-Q93 aggregates visualized in the region from the calyx, (C) that are not detected in the calyx from
control Htt-Q16 animals; bar 10 µm; (E) relative quantification of the fluorescence in (B,C). (D) Confocal
image of the whole brain from third instar larvae expressing Htt-Q93 and GFP (elav-Gal4; Htt-Q93;
mGFP); the Htt-Q93 aggregates are visualized by immunofluorescence and nuclei with DAPI, bar 50 µm.
The yellow squares represent the regions where the Htt-Q93 aggregates were quantified: the Ventral
Nerve Cord (VNC) and the intralobe region (IL), in addition to the calyx. (F,G) Picture representing the
Htt-Q93 aggregates visualized in the intralobe (IL) region from Htt-Q93 (F) or Htt-Q93; GS1 (G) animals;
bar10 µm; the relative quantification analysis is shown from the IL (H) and in the Ventral Nerve Cord
(VNC) (I). Quantification of the aggregate density was calculated in the relative area and measured as
the integrated density of the immunofluorescence signal visualized using anti-human Htt antibody
from 10 confocal z-stacks for each animal and elaborated with ImageJ, (see Materials and Methods).
(J) Filter trap analysis using lysates from the brains of the indicated transgenes; the expression of actin
in the same extracts was analyzed by western blot as an internal control for loading. (K) Confocal
image of elav-Gal4; Htt-Q93 adult female’s head at 10 DAE, immunostained with anti-hHtt antibody
showing the presence of Htt-Q93 aggregates (RED, nuclei DAPI), bar 100 µm. (L) Quantification of
the Htt-Q93 aggregates in the heads of the animals of the indicated genotypes from confocal z-stacks;
analysis was performed in the area indicated by the square. (M) Filter trap analysis of Htt-Q93 protein
aggregates using lysates from the heads. Actin was used as the internal control. The ** p < 0.01,
*** p < 0.001, **** p < 0.0001, values in panels (E,I,J,M) were calculated from Student’s t-test from at least
three independent experiments, where error bars indicate the standard deviations. OL = optic lobe.
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3.4. GS1 Induces Autophagy in Neurons
Neurons employ autophagy to efficiently clear cellular debris that are detrimental for their
homeostasis, including toxic protein aggregates [36]. To investigate whether GS1 may activate the
autophagy–lysosomal pathway, we analyzed whether or not its expression induces the formation of the
characteristic autophagosome vesicles, visible as autophagic puncta and marked by the ubiquitin-like
protein Atg8a, the homolog of the human LC3, that localize at the autophagosome [37]. We used
Atg8a fused with the mCherry-reporter [38] that was co-expressed with mGFP in neurons using
the elav-Gal4 promoter. Fluorescence associated to mCherry-Atg8a was analyzed in the third instar
larvae, specifically in the neurons of the calyx (Figure 4A,D–G), the Ventral Neuronal Cord (VNC)
(Figure 4A), and the retina (Re) (Figure 4A,I). Quantification of this analysis showed that the expression
of UAS-GS1 was able to significantly rescue the reduction in the number of autophagic puncta induced
by UAS-HttQ93 in all the regions analyzed (Figure 4J,K,L), in addition its expression induced the
formation of autophagosomes particularly significant in cells of the calyx and of the VNC (Figure 4J,K).
A similar analysis was performed in adults, where the integrated density of the autophagic puncta was
quantified in female’ brains at 10 DAE (Figure 4H). These data are consistent with those from larval
brains, and showed that the co-expression of GS1 with Htt-Q93, resulted in a significant rescue of the
autophagic puncta (Figure 4M; ANOVA p < 0.01). No significant differences were found in the number
of autophagosomes between UAS-Htt-Q93, GS1 and UAS-GS1 animals (ANOVA p = ns).
3.5. GS1 Rescue of Htt-Q93 Motility-Defect Depends on the Full Expression of Atg1 and Atg5
We then analyzed genetically whether the ability of GS1 to ameliorate the motility in Htt-Q93
animals was dependent upon a functional autophagic pathway. Using the RNAi technique, we
reduced the expression of Atg1/ULk1 or Atg5, key components of the macroautophagy pathway [39] in
combination with the expression of GS1. This analysis showed that the ability of GS1 to ameliorate
the climbing defects of Htt-Q93 animals was significantly reduced when Atg1 or Atg5 expression was
reduced (Figure 5A, Htt-Q93, GS1 vs., Htt-Q93, GFP; Atg1-RNAi ANOVA p < 0.0001; and Htt-Q93, GS1
vs., Htt-Q93, GFP; Atg5-RNAi ANOVA p < 0.0001), suggesting that the rescue exerted by GS1 requires
a functional autophagic pathway. The efficiency of the Atg1 and Atg5 RNAi lines to reduce autophagy
and the relative protein levels was tested (Supplementary Figure S9).
In autophagy, the maturation of the phagosome determines the amount of LC3 (Atg8a in Drosophila),
that is recruited to the vesicles. This depends on the presence of p62/SQSTM1 (sequestosome1)
(Ref(2)P in Drosophila) that is necessary for the recruitment of the ubiquitinated substrates to the
autophagosomes [40,41]. The expression levels of Atg8a and Ref(2)P proteins are used in Western blot
to mark a functional autophagic flux. Atg8a-I protein (15 KDa) is lipidated and cleaved to yield a
fast-migrating band of approximately 7 KDa (Atg8a-II), while its direct interaction with Ref(2)P, by
virtue of its ubiquitin-associated domain, results in Ref(2)P degradation. Our analysis showed that in
the presence of GS1 the amount of the fast-migrating Atg8a-II band significantly increased, and this
was visible also when GS1 was co-expressed with Htt-Q93 (Figure 5B,C). Analysis of SQSTM1/Ref(2)P
expression levels showed two distinct bands of approximately 100 and 62 KDa recognized by the
Drosophila antibody, that were both significantly reduced in the presence of GS1 (Figure 5B,C), and also
when GS1 was co-expressed with Htt-Q93 (Figure 5B,C). All together these data support the hypothesis
that GS1 promotes in neurons a small but active autophagic flux.
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Figure 4. Expression of GS1 in neurons induces autophagy. (A) Confocal image of whole the brain from
a third instar larva showing the pattern of expression for elav-mCherryAtg8a; GFP where the autophagic
puncta are marked in red and neurons by GFP; the images represent the pattern of expression of
elav-mCherryAtg8a from animals expressing UAS-GS1. (B,C) Insets showing a higher magnification of the
right calyx from A; neurons are visualized by lav-GFP. (B) and autophagic puncta by elav-mCherryAtg8a
(C); bar 10 µm. Autophagic puncta were analyzed in the regio of th calyx (D–G), retina (Re) (I) and in
the Ventral Nerve Cord (VNC ; OL = op ic lobe. (D–G) representative images sh w ng mCherryAtg8a
staining i the calyx of the animals at the indicated genotypes, (a higher mag ification of these images
is shown in Supplement ry Figure S10). (H) I e of an elav-mCherry-Atg8a; mGFP f male’s head
at 10 DAE; OL = optic lobe; bar 100 µm. (I) Imag of n eye disc from a third instar elav-GS1 larva
co-expressing mCherry-Atg8a in neurons of the retina and in the pigmented cells, with the nuclei
stained in blue; bar 50 µm. (J–M) Quantification of autophagy was measured as the integrated density
of mCherry-Atg8a and then converted in autophagosome density (see methods). Autophagosome
density in neurons of the calyx (J), in the Ventral Nerve Cord (VNC), (K) in the retina (L), and in
the adult heads (M) from animals of the indicated genotypes. One-way ANOVA p-values analysis:
**** p < 0.0001, ** p < 0.01, * p < 0.05 were calculated from a minimum of five animals, error bars indicate
the standard deviations.
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Figure 5. Reduction of Atg1 and Atg5 significantly impairs the ability of GS1 to rescue the motility
defects induced by Htt-Q93. (A) 15 adult females were used for each genotype and their % of success in
motility reported in the graph, the p-values from the one-way ANOVA are reported in the Excel file 1.
(B) The presence of GS1 favors Atg8a cleavage and reduces the presence of Ref(2)P. Western blots from
heads of females at 10 DAE of the indicated genotype, showing the pattern of expression of Atg8a-I
and II and of SQSTM1/Ref(2)P, note that in Drosophila the latter runs in two isoforms of about 100 and
62 KDa, both recognized by the Drosophila antibody. Tubulin was used as the control for loading.
Experiments were repeated at least twice with similar results. 10 heads were used for each genotype.
(C) The ratio for Atg8a-II/I and Ref(2)P/tubulin were calculated by comparing the quantification of the
relative proteins with ImageJ to that in control Htt-Q16 animals, previously normalized to tubulin. We
calculate the ratio using the 100 KDa isoform, since it is described as the ortholog of human p62 [41].
One-way ANOVA p-values: *** p < 0.001, ** p < 0.01, * p < 0.05 were calculated from two independent
experiments of animals, and error bars indicate the standard deviations.
3.6. Expression of GS1 Reduces TOR Activation Visible by Phosphorylation of Its Substrate S6K
When it is activated, TOR translocates onto the lysosomal membrane where it assembles in
the TORC1 complex, r sulting in its activati and phosphorylation of the downstream targets S6K
and 4EBP [42]. To explore the bility f GS1 to affect TOR activation, e an lyzed the level of
phosphorylati n of its target S6K on Thr-398, an event that is conserved also in Drosophila S6K [43] in
lysates from the heads. This analysis revealed that expression of UAS-GS1 i neur ns significantly
reduced the levels of S6K phosphorylation (Figure 6A,B, ANOVA p < 0.001), and a similar result was
obtained when UAS-GS1 was co-expressed with UAS-Htt-Q93 (Figure 6A,B, ANOVA p < 0.05). Overall
these new data suggest that GS1 activity could influence the level of essential amino acids involved in
TOR activation, resulting in the inhibition of TOR complex1 and of the downstream phosphorylation
of its targets including S6K.
3.7. Expression of GS1 in Neurons affects Glutamate and Glutamine Levels and Reduces Essential Amino Acids
In order to test if expression of GS1 affected the level of glutamate (Glu) and glutamine (Gln)
we next performed analysis of these amino acids, from the heads of our relative animals. This data
revealed that in general glutamate levels are increased in the head of animals expressing Htt-Q93 in
neurons (Figure 7A, solid black vs. solid red columns, t-test p < 0.0001). Moreover, expression of GS1
together with Htt-Q93 significantly reduced this effect (Figure 7A, solid red vs. solid purple columns,
t-test p < 0.05), and a small but significantly increase in Gln levels was still observed (Figure 7A, empty
red vs. empty purple columns, t-test p < 0.05). Expression of GS1 alone did not affect Glu concentration
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(Figure 7A solid black vs. brown columns, t-test ns) but significantly increased the levels of Gln
(Figure 7A, empty black vs. empty brown columns, t-test P<0.0001). Suggesting that GS1 is able to
convert Glu into Gln particularly when the levels of Gln are increased like in the presence of Htt-Q93.
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Figure 6. Expression of GS1 in neurons reduces S6K phosphorylation. (A) Western blot showing
the level of phosphorylated S6K on Thr 398 and of S6K in lysates within 10 heads from animals
expressing the indicated transgenes in neurons using the elav-Gal4 driver. Actin was used as the loading
control. (B) Gra ic representing the ratio of S6K phosphorylation versus the unphosphorylated
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t-test from at least three independent experiments; the error bars indicate the standard deviations.
To better identify the effect of GS1 o the lev l of expression of ther amino acids, we analyzed
the profile of Essential a ino acids (EAA) and Non-Essential amino acids (NEAA) fr m the heads of
animals expressing GS1 in neurons, and compared it to that from control Htt-Q16 flies (Figure 7B).
These data confirmed that Gln concentration was significantly increased upon GS1 expression (p < 0.01)
and that Glu level was reduced (p < 0.05). In addition, EA : isoleucine (Il ), phenylalanine (Phe),
histidine (His) and NEAA:argi ine (Arg), proline (Pro), serine (Ser) and aspartic acid (Asp) were
also significantly reduced. Moreover, these data revealed the unexpected ability of GS1 to increase
asparagine (Asn) level while reducing aspartic acid (Asp). This last observation, together with the
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increase of the Gln level, may suggest a novel role for this enzyme in neurons to activate asparagine
synthetase (ASNS), an enzyme that hydrolyzes Gln to produce Asn from Asp and Glu. Notably, this
enzyme was previously described in mammals as activated to bypass amino acid starvation and
production of Asp necessary to sustain protein synthesis and cell survival [44].
3.8. Fibroblasts from Patients with Huntington’s Disease Have Impaired Autophagy and Reduced Level of GS1
Since autophagy is known to be defective in HD [45,46], we analyzed whether the autophagic
flux was compromised in fibroblasts derived from patients carrying different lengths of the (CAG)s in
the exon1-of the Huntingtin gene (Htt). Analysis by Western blot on the level of hHtt protein expression
in these cells (Figure 8A) showed the presence in all the samples of a band running above 250 KDa,
possibly the full-length Htt protein with the predicted size of 350 KDa [47]. In addition, we observed
a band of about 70 KDa only present in lysates from cells derived from patients carrying in the Htt
gene a sequence of 78–90 CAG repeats (mHTT). A band of about 55 KDa was present in all the samples
but more evident in lysates from fibroblasts from healthy donors carrying a sequence of about 17–33
CAG repeats in the Htt gene (wt-Htt). The human huntingtin protein is cleaved by calpain at around
amino acids 437–586 to generate a series of proteolytic fragments of about 50 KDa [48], we believe
that the difference in the molecular weight observed in the western blot of the HTT proteins, is due
to the presence of a the CAGs sequence in the proteolytic fragments of the mHTT that runs at about
70 KDa, as compared to 50 KDa in extracts from fibroblasts from healthy donors, that is recognized by
the anti-N-terminus Htt antibodies.
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(A) Western blot showing the attern of expression of human Htt pr tein in fibroblasts from control
healthy dono (C1–C3), with an average of 15–33 CAGs, or from HD pat ents (HD1–HD4) with an
average of 78–90 CAGs. The anti-hHtt antibodies evidence the presence of a band of about 70 KDa
(mHTT) that is visible only in lysates from cells deriving from HD patients, while in the lysates form
controls, a band below 55 KDa is evident and preferentially expressed in healthy donors (wt-Htt).
Experimen s were repeated at l ast twice, da a were analyzed from al least three different patients or
controls, and a representative situation is shown. (B) Western blot showing the cleavage of LC3 protein
in the lysates of fibroblasts from control healthy donors and from HD patients. The fast-migrating
form of LC3-II (upper panel) is significantly reduced in the extracts from fibroblasts of HD patient
as compared to lysates from contr l don rs. Actin is shown as a contr l f r loading (lower panel).
(C) Quantification of the ratio LC3-II/I from (B). (D) Western blot showing that expression of GS1 in
fibroblasts from HD patients is reduced compared to its expression in control donors, tubulin was used
as a control for loading. (E) relative quantification analysis of GS1 in fibroblasts from (D). The p values
were calculated from Student’s t-test from the relative number of samples.
The proteolytic cleavage of LC3 is considered a hallmark of autophagy, our analysis showed
that in cells from HD patients, the f st-migrating bands, correspondi g to the cleaved LC3-II form, is
significantly reduced compared to its level in fib blasts from control healthy donors (Figure 8B,C,
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Student t-test p-0.0341), suggesting that the autophagic flux has been compromised in HD cells. In
addition, we analyzed the level of GS1 protein expression by western blot, and to our surprise, we
found that GS1 protein was 45% reduced in fibroblasts from patients, as compared to that in fibroblasts
from control donors (Figure 8D,E, Student t-test p = 0.0132). Taken together, these data from human
cells corroborate our results described in flies that suggest a potential novel conserved function for GS1
to control autophagy, a function that may be impaired in pathological conditions such as HD.
4. Discussion
The glutamate–glutamine cycle (GGC) is a sequence of biochemical events between neurons
and glia necessary for the control of glutamate homeostasis. Previous studies showed that this cycle
is impaired in mouse and Drosophila models for HD [49,50]. In addition, the activity of Glutamine
Synthetase 1 (GS1), a key regulator of the GGC, was found to have been reduced in post mortem brains
of HD patients [51,52]. To elucidate the role of GS1 in HD, we modulated its activity in neurons using
a Drosophila model expressing the mutated human exon1 Htt-Q93 that mimics many aspects of the
neurodegeneration induced by toxic polyglutamine expansion in HD patients [34]. Our data show that
neuronal expression of the Drosophila homolog of human GS1 ameliorates animal motility and reduces
neuronal death induced by the expression of Htt-Q93.
Moreover, we found that co-expressing GS1 with Htt-Q93 reduces the size of the toxic Htt-Q93
aggregates, and increases the levels of macro-autophagy, herein referred to as autophagy, establishing
a novel link between the GGC and functional autophagy in post-mitotic cells.
Autophagy has a well-established beneficial role in several processes relevant for neurons under
both normal and pathological conditions [6,53]. It is a conserved mechanism controlled by key
proteins like Atg1/ULK1, a kinase essential for the initial formation of the complex, then Atg5, that is
involved together with LC3/Atg8a in the autophagosome maturation and lipidation of LC3/Atg8a to
its proteolytic cleavage to Atg8-II. p62/SQSTM1/Ref(2)P binds to the autophagosome-coating protein
LC3/Atg8a and activates the fusion of the phagosome with the lysosome to degrade its cargo [21].
Polymorphisms in the ATG genes, including ATG5 and ATG7, have been associated with an early
onset of neurodegenerative diseases, including HD [54]. Moreover, the important role of autophagy
in neurons was revealed by the conditional knock-out of ATG5 and ATG7 that results in progressive
motoneuron defects, alteration in autophagosome formation and accumulation of ubiquitin-positive
protein aggregates in degenerating neurons [55–57]. These phenotypes are conserved in Drosophila,
where atg7D77 mutants have a short life-span, reduced motility and the accumulation of ubiquitinated
proteins [58].
Our data show that the ability of GS1 to ameliorate the motility of Htt-Q93 flies depends on a
functional autophagic pathway since the reduction of atg1 and atg5 completely abolished the rescue
by GS1. Moreover, the presence of GS1 in neurons enhances the cleavage/lipidation of Atg8 (Atg8-II)
and reduces the level of Ref(2)P/SQSTM1, suggesting an increase of the autophagic flux in neurons.
Autophagy is inhibited by nutrients and amino acids that induce TORC1 activation [10,21]. Stimulation
of TORC1 at the lysosome membrane depends on the ability of amino acids to activate the Rag(s)
(GTPases), the Ragulator complex and the vacuolar H+ adenosine triphosphatase (v-ATPase) [59].
However, TOR activity is controlled specifically by certain branches of amino acids [60], most relevantly,
glutamine [61,62], leucine [42,61,63], and arginine [64].
Our data show that expression of GS1 reduces the phosphorylation of the S6K protein, a target of
TOR complex 1, thereby suggesting that it plays a role in the regulation of its activity. GS1 converts
glutamate (Glu) into glutamine (Gln), and amino acids analysis shows that expression of GS1 alone or
in the presence of Htt-Q93 increases the level of Gln (Figure 8B). Gln is involved in a multiplicity of
metabolic pathways, and its function in TOR signaling still presents some controversial results. Gln
in epithelial cells binds to the adenosine diphosphate ribosylation factor-1 GTPase (Arf1) to directly
activate TORC1 at the lysosome membrane [60]. Our data in neurons however show that in the
presence of GS1, TOR signaling is reduced even if the glutamine level increases, so this may suggest
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that in terminally-differentiated cells, GS1 induces a “starvation-like” condition that favors autophagy
without the activation of TORC1. In support of this mechanism, van der Vos and colleagues showed
that in cancer cells under nutrient starvation, transcriptional induction of GS1 by FOXO3 resulted in
autophagy and survival with the concomitant inhibition of the TOR pathway [65]. We do not know
at the moment if this pathway may be responsible for any GS1 activation in neurons, but we found
that the expression of Drosophila FOXO transcriptionally induces dGS1-mRNA, suggesting that this
regulation is conserved also in flies (Supplementary Figure S5).
Expression of GS1 also reduces the level of Glu, a nonessential amino acid that functions as
excitatory neurotransmitter in the central nervous system, and acts as a substrate in many distinct
biochemical reactions [66]. Glu is synthesized from Gln, α- ketoglutarate and 5-oxoproline as a
precursor for the biosynthesis of various amino acids including proline (Pro) and arginine (Arg) [67,68].
Interestingly, in the heads of animals expressing GS1, we found reduced levels of Pro and Arg, both
relevant amino acids in the mechanism of TOR activation through specific amino acid sensors [59].
In particular, the lysosomal amino acid transporter SLC38A9 was proposed relevant for TOR activation
by Arg in mammalian epithelial cells [69]. So far, there are no data describing the mechanism of
activation by SLC38A9 in neurons. However, since we found Arg levels reduced in the heads of
animals expressing GS1, while Gln levels were high, we speculate that Arg activation of SLC38A9 in
neurons may act downstream of Gln in the stimulation of TOR pathway, since Gln is not a limit factor.
It is worthy to note that, although the Drosophila SLC38A9 transporter has not been characterized
yet, the Drosophila genome contains three genes expressed in the brain (CG13743, CG30394 and
CG320181) [70–72], whose sequences are significantly homologous to that of human SLC38A9 [73],
suggesting that they may encode for the fly functional homolog(s) of SLC38A9.
Our data also show that GS1 increases the level of Asn while the level of Asp decreased, suggesting
an upregulation of asparagine synthetase (ASNS), a transaminase that is induced during nutrient
starvation to indirectly synthetize amino acids (Asn) to sustain protein synthesis [44,69,74,75]. Similarly,
we saw the levels of alanine (Ala) increased, suggesting the activation also of alanine synthetase,
another transaminase, whose level of activation may be stimulated when glutaminolysis is higher to
produce Glu from Gln to support metabolic pathways of the biosynthesis of proteins [76].
Finally, we analyzed autophagy in human fibroblasts derived from healthy donors or patients with
HD. These experiments revealed that fibroblasts carrying the mHtt suffer of a defect in the expression
and possible cleavage of the LC3 gene/protein, suggesting that autophagy is impaired in these cells.
These data allow to postulate that autophagy may be defective also in post-mitotic, primary neurons
from HD patients; in the near future we would like to carry out experiments to validate this hypothesis
in neuronal cells derived from iPSCs from donors or from patients carrying different CAGs mutations
in the huntingtin gene.
In summary, malfunctions in the components of the glutamate–glutamine cycle have been detected
in many neurodegenerative diseases, including Huntington disease [51,77,78]. Here we show a novel
function for GS1, a member of the GGC, to control autophagy in post-mitotic cells, like neurons that
are highly dependent on the endo–lysosomal pathway for their functional homeostasis. The function
of GS1 in neurons may be important for the control of essential amino acids, including the switch to
increase Asn, indicating a role in the biochemical homeostasis of neurons that maintain autophagy
active. Here we can speculate that this function for GS1 in controlling autophagy is conserved also in
humans, as fibroblasts from HD patients have defective autophagy due to the reduced level of LC3
accompanied by a reduction in GS1 levels.
Supplementary Materials: The following are available online at http://www.mdpi.com/2073-4409/9/1/196/s1;
Supplementary Figure S1: ClustalW amino-acid sequence alignment of Drosophila GS1 (UniProt E1JHQ1) and of
human GLUL (UniProt P15104); Supplementary Figure S2: Reduction of GS1 enhances retinal defects induced by
Htt-Q93; Supplementary Figure S3: Expression of GS1 rescues neuronal death induced by Htt-Q93; Supplementary
Figure S4: Schematic representation of the N-terminus region of the huntingtin protein and time line of the advent
of the motility defects induced by Htt-Q93 expression; Supplementary Figure S5: Expression of GS1 induces
FOXO-mRNA; Supplementary Figure S6: In adult males, co-expression of GS1 with Htt-Q93 in neurons partially
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Supplementary Video S3: adult climbing elav-Htt-Q93 and elav-Htt-Q16.
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